Previous 10 | Next 10 |
804 Alzheimer’s Patients Are Enrolled in a Pivotal Phase 3 Clinical Trial A Second Pivotal Phase 3 Clinical Trial Is Expected to Complete Enrollment Q4 2023, With a Target Enrollment of Approximately 1,100 Patients. AUSTIN, Texas, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cassava S...
2023-09-30 18:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-09-21 04:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-09-18 10:36:29 ET More on Cassava Sciences Cassava Sciences: Insiders Purchasing Stock, Is The Market Still Buying Simufilam? Cassava Sciences: CMS Data Promising But Many Red Flags Remain; Hold Cassava Sciences: Quest For Alzheimer's Treatment A Risky Bet On Si...
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials. The DSMB Recommended the Phase 3 Trials of Simufilam Continue as Planned, Without Modification AUSTIN, Texas, Sept. ...
2023-09-14 13:02:36 ET More on Alzheimer's drug developers Cassava Sciences: Insiders Purchasing Stock, Is The Market Still Buying Simufilam? Prothena: Dunn Appointment And Bristol Opt-In Boost Validation Anavex Life Sciences: Multiple CNS Shots On Goal Awaiting Conv...
2023-09-11 14:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease. Results corroborate prior research from other academic researchers. These data once again confirm the biological activity of simufilam. AUSTIN, Texa...
2023-09-07 11:04:48 ET More on Lilly, Novo, etc. Novo Nordisk: Super Focused Pharma Company For The Long Run Novo Nordisk: Strong Fundamentals Meet Technical Uptrends Eli Lilly And Novo Nordisk: Are Weight Loss Drugs A Global Revolution Or Short-Lived Fad? Se...
AUSTIN, Texas, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it has been invited to present at the following investor conferences. A webcast or subsequ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...